Clinical trials: Hematologic Malignancies
Advanced Haematological Malignancies
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up.
- Trial name
- NCT04630756
- Testing
- AZD4573, Acalabrutinib
- Where
- 17 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM.
- Trial name
- MyHOPE™ (NCT04730505)
- Testing
- MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
- Where
- 34 sites in United States
- Volunteers
- 2 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
Relapsed or Refractory Multiple Myeloma
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
The purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.
- Trial name
- NCT05503550
- Testing
- Talquetamab
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
The study objectives of this study are to determine the effects, safety, and pharmacokinetics of bendamustine for multiple myeloma to a regimen of bendamustine and prednisolone.
- Trial name
- NCT01179490
- Testing
- SyB L-0501, prednisolone
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- SymBio Pharmaceuticals
Refractory Hematologic Cancer
A Study of BMS-863233 in Patients With Hematologic Cancer
To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects with Refractory Hematologic Cancer
- Trial name
- NCT00838890
- Testing
- Cdc7-inhibitor (BMS-863233)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Myelofibrosis
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants.
- Trial name
- SENTRY (NCT04562389)
- Testing
- Selinexor, Ruxolitinib
- Where
- 166 sites in United States, Australia and 18 more
- Volunteers
- 353 people
- Sponsor
- Karyopharm Therapeutics Inc
Follicular Lymphoma (FL), CLL
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
- Conditions
- Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome
- Trial name
- KEYNOTE145 (NCT02362035)
- Testing
- Acalabrutinib, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 161 people
- Sponsor
- Acerta Pharma BV
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
B-Cell Chronic Lymphocytic Leukemia
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL).
- Trial name
- NCT01144260
- Testing
- bafetinib
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- CytRx
Multiple Myeloma
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
This is a multicenter, open-label, phase 1, single arm study intended to determine the optimal target dose and safety of bb2121 in subjects with HR (R-ISS Stage III per IMWG criteria) NDMM.
- Trial name
- KarMMa-4 (NCT04196491)
- Testing
- bb2121, Fludarabine, Cyclophosphamide
- Where
- 22 sites in United States
- Volunteers
- 13 people
- Sponsor
- Celgene
Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
The main objective is to assess the safety, tolerability, and efficacy of AMG 176 as monotherapy and in combination with the 7-day regimen of azacitidine for the treatment of Higher-Risk Myelodysplastic Syndrome and Chronic…
- Trial name
- NCT05209152
- Testing
- AMG 176, Azacitidine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Lymphocytic Leukemia, Chronic
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
This open-label, 2-arm, nonrandomized, multicenter, Phase Ib study will investigate the safety and efficacy of obinutuzumab (RO5072759; GA101) administered in combination with chemotherapy (bendamustine or fludarabine +…
- Trial name
- NCT01300247
- Testing
- Fludarabine, Obinutuzumab, Bendamustine
- Where
- 18 sites in United States
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Anemia, Cancer
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
The purpose of this study is to evaluate the hematologic response, safety, and clinical outcomes of PROCRIT administered once a week in anemic cancer patients receiving chemotherapy.
- Conditions
- Anemia, Cancer, Chemotherapy
- Trial name
- NCT00341055
- Testing
- Epoetin alfa
- Volunteers
- 69 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
CML (Chronic Myelogenous Leukemia)
Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment
The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with…
- Trial name
- NCT07651878
- Testing
- vididencel
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- Mendus
Leukemia, Myeloid, Acute
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML…
- Trial name
- NCT03388749
- Testing
- Liposomal Annamycin
- Where
- 5 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Moleculin Biotech, Inc.
Head and Neck Neoplasm, Prostatic Neoplasm
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET] scans due to advanced non-hematologic…
- Conditions
- Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
- Trial name
- NCT00666926
- Testing
- PF00562271
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 99 people
- Sponsor
- Verastem, Inc.
Chronic Myeloid Leukemia
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II open-label trial of subcutaneous HHT (omacetaxine mepesuccinate) in the treatment of patients who are resistant to or intolerant to Tyrosine Kinase Inhibitors.
- Trial name
- NCT00462943
- Testing
- Omacetaxine mepesuccinate
- Where
- 29 sites in United States, Canada and 8 more
- Volunteers
- 100 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsed or Refractory Multiple Myeloma
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
- Trial name
- NCT07116616
- Testing
- mRNA-2808
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ModernaTX, Inc.
Chronic Myeloid Leukemia, Blast Crisis
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are currently in the myeloid blast phase of chronic myeloid leukemia (CML) and who are either resistant to or intolerant of…
- Trial name
- NCT00101816
- Testing
- Dasatinib
- Where
- 62 sites in United States, Australia and 18 more
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.